Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04746456 · ClinicalTrials.gov registry record
Vulvovaginal Atrophy Questionnaire (VVAQ): Psychometric Validation of a Novel PROM
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 210
- Enrollment target
NCT04746456: Completed study, sponsored by Massachusetts General Hospital.
NCT04746456 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 210 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04746456 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 210 participants
- Enrollment target
Study Summary
The goal of this study is to perform a quantitative assessment of the psychometric properties of the Vulvovaginal Atrophy Questionnaire (VVAQ), a novel patient reported outcome measure (PROM), through a REDCap survey of menopausal women with and without symptomatic vulvovaginal atrophy (VVA)/genitourinary syndrome of menopause (GSM).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2022-09-01 |
| Est. Completion | 2024-05-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04746456
The ClinicalTrials.gov registry entry for NCT04746456 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04746456 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04746456 about?
NCT04746456 is a clinical study titled "Vulvovaginal Atrophy Questionnaire (VVAQ): Psychometric Validation of a Novel PROM". The goal of this study is to perform a quantitative assessment of the psychometric properties of the Vulvovaginal Atrophy Questionnaire (VVAQ), a novel patient reported outcome measure (PROM), through a REDCap survey of menopausal women with and without symptomatic vulvovaginal atrophy (VVA)/genitou...
What is the current status of trial NCT04746456?
This trial is currently completed. The enrollment target is 210 participants. The study started on 2022-09-01. Estimated completion is 2024-05-01.
Who is sponsoring clinical trial NCT04746456?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.